Statins (Atorvastatin, Rosuvastatin)

What statins are

Statins such as atorvastatin and rosuvastatin are prescription-only cholesterol-lowering drugs. They have been in use for decades. In the longevity scene they have two faces: some see early and consistent LDL lowering as the most important measure against cardiovascular disease, while others fear side effects.

Both sides can be measured against data, and for statins the data are unusually extensive. In addition, there are alternatives and complements such as bempedoic acid for statin intolerance and dietary supplements such as red yeast rice or citrus bergamot.

How they work

In the liver, statins inhibit HMG-CoA reductase, a key enzyme in the body’s own cholesterol production. The liver cells then form more LDL receptors and remove more LDL cholesterol from the blood. In JUPITER, rosuvastatin halved LDL and additionally lowered the inflammatory marker CRP by 37 percent.

What matters is the size of the LDL reduction: in the Cholesterol Treatment Trialists’ meta-analysis, the risk of major vascular events fell by 22 percent per 1 mmol/l of LDL reduction, including in participants whose LDL was already below 2 mmol/l. No lower limit was apparent. How an elevated lipoprotein(a) should be assessed is covered on its own page.

What the studies show

CTT 2010: the relationship between LDL and risk

The Cholesterol Treatment Trialists analyzed individual data from 21 trials of statin versus control and 5 trials of more versus less intensive therapy. More intensive statin therapy lowered LDL by a further 0.51 mmol/l and major vascular events by a further 15 percent. Across all trials, events fell by 22 percent per 1 mmol/l of LDL reduction and all-cause mortality by 10 percent, mainly through fewer cardiac deaths. The authors estimate that an LDL reduction of 2 to 3 mmol/l lowers risk by 40 to 50 percent.

JUPITER 2008: healthy people with elevated CRP

17,802 people without elevated blood lipids but with a CRP of at least 2 mg/l received 20 mg of rosuvastatin or placebo. The trial was stopped early after a median of 1.9 years: heart attack HR 0.46, stroke HR 0.52, death from any cause HR 0.80. Muscle disease and cancer did not increase; physician-reported diabetes occurred more often.

HOPE-3 2016: intermediate risk, 21 countries

12,705 people without cardiovascular disease at intermediate risk received 10 mg of rosuvastatin or placebo for a median of 5.6 years. LDL was 26.5 percent lower, and the primary endpoint occurred in 3.7 versus 4.8 percent (HR 0.76). Diabetes and cancer did not increase; cataract surgery (3.8 versus 3.1 percent) and muscle complaints (5.8 versus 4.7 percent) increased slightly.

SAMSON and StatinWISE: the nocebo effect

In SAMSON, 60 people who had stopped statins because of side effects received monthly doses of atorvastatin, placebo or empty doses for one year. The symptom score was 8.0 without tablets, 16.3 under statin and 15.4 under placebo, with no difference between statin and placebo; 90 percent of the complaints under statin thus also occurred under placebo. Six months later, half were taking statins again (Howard 2021). StatinWISE tested atorvastatin and placebo alternately in 200 people with previous severe muscle complaints: no difference in the muscle symptom score, and two thirds wanted to continue taking statins afterwards (Herrett 2021).

Longevity: what is known beyond the heart

In the US lifespan program ITP, the combination of atorvastatin and telmisartan did not extend the lives of mice (Korstanje 2026). In humans, STAREE is intended to clarify whether atorvastatin extends disability-free survival in 9,971 people aged 70 and over; the trial is no longer recruiting, and results have not yet been published.

Where the data stop

• An anti-aging effect beyond cardiovascular prevention. All-cause mortality falls because fewer people die of heart disease. An effect on aging beyond this has not been shown in humans, and in the ITP mouse program a statin combination did not extend lifespan.
• The benefit in the very old without prior disease. For people aged 70 and over without cardiovascular disease, the answer from STAREE is still pending.
• That every muscle complaint is nocebo. There is a small real effect, especially in the first year and at high doses. However, it explains only a small part of the complaints.
• The benefit at very low baseline risk. The relative effect is similar across risk groups, but the absolute benefit depends on the individual baseline risk. In HOPE-3, the groups at intermediate risk were 1.1 percentage points apart.

Status, approval and legal

Statins are approved, prescription-only medicines in Germany; atorvastatin, rosuvastatin and simvastatin are listed in Annex 1 of the German Prescription Drug Ordinance (Arzneimittelverschreibungsverordnung). There are numerous generics.

Whether a statin makes sense depends on the individual cardiovascular risk, which is estimated by a physician. Taking it solely for the purpose of extending life without elevated risk is not covered by the approval.

Safety

The side effects of statins have been studied better than those of almost any other long-term medication. Real but small effects are: in the first year, 11 additional reports of muscle pain or weakness per 1,000 person-years, slightly more at high doses (CTT 2022); slightly more newly diagnosed diabetes (JUPITER); elevated liver values in 0.30 versus 0.22 percent per year (CTT 2026).

Many other complaints listed in product information, including memory problems, depression, sleep disorders and nerve damage, did not occur more often under statins than under placebo in double-blind trials. The authors of this analysis therefore call for the product texts to be revised (CTT 2026). Anyone who notices complaints while taking a statin should discuss this with a physician.

Sources

• Cholesterol Treatment Trialists (CTT) Collaboration, Lancet 2010 – meta-analysis, 26 randomized trials with about 170,000 participants
• Ridker PM et al., N Engl J Med 2008 – JUPITER, rosuvastatin in 17,802 apparently healthy people with elevated CRP
• Yusuf S et al., N Engl J Med 2016 – HOPE-3, rosuvastatin in 12,705 people at intermediate risk without cardiovascular disease
• Howard JP et al., J Am Coll Cardiol 2021 – SAMSON, statin, placebo and empty months in 60 people who had stopped statins
• Herrett E et al., BMJ 2021 – StatinWISE, 200 N-of-1 trials on muscle complaints under atorvastatin
• Cholesterol Treatment Trialists Collaboration, Lancet 2022 – muscle complaints under statins, 19 double-blind trials with 123,940 participants
• Cholesterol Treatment Trialists Collaboration, Lancet 2026 – assessment of the statin side effects listed in product information using double-blind trials
• Korstanje R et al., GeroScience 2026 – ITP, including atorvastatin plus telmisartan without lifespan extension in mice
• ClinicalTrials.gov NCT02099123 – STAREE, atorvastatin for disability-free survival in 9,971 older people aged 70 and over
• German Prescription Drug Ordinance (AMVV), Annex 1 – atorvastatin, rosuvastatin and simvastatin prescription-only